ALLMedicine™ Renal Cell Carcinoma Center

May 18th, 2022 - In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise syst...

May 17th, 2022 - Level I evidence has failed to demonstrate an overall survival (OS) advantage for cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma (ccRCC) in the modern era, which is at odds with observational studies reportin...

May 17th, 2022 - Adjuvant drugs are used to reduce the risk of tumor recurrence in patients with cancer who are successfully treated with first-line therapy. The same drugs used in the metastatic or first-line setting are often used in the adjuvant setting, and al...

May 17th, 2022 - A Mexican woman, aged 60 years, presented with fevers and abdominal pain. She had initially presented to an outside emergency department with weakness, malaise, nausea, vomiting, tachycardia to 110s, and fever to 102 °F. Her medical history was re...

May 17th, 2022 - Renal cell carcinoma is now increasingly treated with checkpoint inhibitor therapy, predominantly in the metastatic setting or occasionally in the adjuvant setting; however, there is little published histopathology data demonstrating the post-ther...

May 14th, 2022 - Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic ...

Jan 7th, 2022 - The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor hist...

Oct 13th, 2021 - Advance diagnostic and treatment modalities have improved outcomes for renal cell carcinoma (RCC) patients, but the prognosis for those with metastatic disease (mRCC) remains poor. As given metastatic distribution is critical in guiding treatment ...

Oct 12th, 2021 - Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking.

Oct 2nd, 2021 - ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.|2021|Powles T,Albiges L,Bex A,Grünwald V,Porta C,|drug therapy,drug therapy,

May 13th, 2022 - Background: Rare histological variants of the GU tract include bladder/urachal adenocarcinoma, squamous cell carcinoma, and small cell carcinoma; variants of urothelial carcinoma including plasmacytoid, sarcomatoid; renal tumors including sarcomat...

May 13th, 2022 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma. HLRCC is caused by mutations i...

May 12th, 2022 - The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

May 11th, 2022 - Patients with localized and non-metastatic Renal Cell Carcinoma (RCC) represent an "at-need" population who would benefit from immunotherapy earlier in their disease course with a programmed cell death protein 1(PD-1) therapy combined with a secon...

May 11th, 2022 - The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC). There will be two cohorts in this study: Cohort A will consist of participants with clear cell (...

May 6th, 2022 - China-based Hutchmed announced receipt of a complete response letter from the FDA, stating that the agency cannot approve the tyrosine kinase inhibitor surufatinib for advanced neuroendocrine tumors without support from a multiregional clinical tr...

May 4th, 2022 - Tian Zhang, MD: Dr Barata, can you provide a brief overview of some ongoing neoadjuvant therapy trials? In particular, we saw some data from one of the first IO [immunotherapy]/VEGF combination trials to report out, avelumab and axitinib, at ASCO ...

May 2nd, 2022 - Transcript: Robert J. Motzer, MD: Two last quick points for you. Cabozantinib is 1 of our main go-to drugs for RCC [renal cell carcinoma]. It’s been proposed to be particularly effective for bone metastases, right? There were recent data for cabo...

May 2nd, 2022 - Arnab Basu, MD: In your experience, what are some of the commonly observed adverse events in this IO [immunotherapy]/IO combination therapy regimen, and how do you manage those? Shawnta Anakwah, MD: Typically, the ones that I’ve seen have been ra...

Apr 28th, 2022 - Although the microorganisms colonizing our bodies have long been linked to human health and various disease states, an understanding of the potential impact of the microbiota on cancer has just begun to emerge in the past 20 years. Novel strategie...